Status:
COMPLETED
Dopamine and Norepinephrine in Shock Patients
Lead Sponsor:
Sepsis Occurrence in Acutely Ill Patients
Conditions:
Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy of dopamine and norepinephrine, two commonly used vasopressor agents, in the treatment of shock.
Detailed Description
Introduction: Vasopressor agents are commonly used to correct hypotension in patients with acute circulatory failure. Their variable alpha, beta, or dopaminergic receptor stimulation, may result in d...
Eligibility Criteria
Inclusion
- Mean arterial pressure less than 70 mmHg or systolic pressure less than 100 mmHg persisting despite adequate fluid loading (in example with at least 1000 mL crystalloid or 500 ml colloid) unless central venous pressure (CVP) or pulmonary artery occluded pressure (PAOP) are elevated (e.g. CVP\> 12 mmHg or PAOP \> 14 mmHg).
Exclusion
- Serious arrhythmia such as rapid atrial fibrillation (\> 160/min) or ventricular tachycardia.
- Brain death.
- Open label administration of dopamine, norepinephrine, epinephrine or phenylephrine for more than 4hours.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
1679 Patients enrolled
Trial Details
Trial ID
NCT00314704
Start Date
December 1 2003
End Date
October 1 2007
Last Update
February 1 2010
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Vienna
Vienna, Austria, 1090
2
CHU Saint Pierre
Brussels, Belgium, 1000
3
CHU Brugmann
Brussels, Belgium, 1020
4
HIS Ixelles
Brussels, Belgium, 1050